WallStSmart

EastGroup Properties Inc (EGP)vsLineage, Inc. Common Stock (LINE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Lineage, Inc. Common Stock generates 628% more annual revenue ($5.36B vs $735.38M). EGP leads profitability with a 39.8% profit margin vs -1.9%. EGP earns a higher WallStSmart Score of 61/100 (C+).

EGP

Buy

61

out of 100

Grade: C+

Growth: 8.0Profit: 8.0Value: 4.0Quality: 5.0

LINE

Avoid

34

out of 100

Grade: F

Growth: 3.3Profit: 3.5Value: 6.7Quality: 3.8
Piotroski: 5/9Altman Z: 0.81
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EGPUndervalued (+2.3%)

Margin of Safety

+2.3%

Fair Value

$194.37

Current Price

$198.34

$3.97 discount

UndervaluedFair: $194.37Overvalued
LINEUndervalued (+75.9%)

Margin of Safety

+75.9%

Fair Value

$161.49

Current Price

$36.50

$124.99 discount

UndervaluedFair: $161.49Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EGP4 strengths · Avg: 9.5/10
Profit MarginProfitability
39.8%10/10

Keeps 40 of every $100 in revenue as profit

Operating MarginProfitability
40.2%10/10

Strong operational efficiency at 40.2%

EPS GrowthGrowth
55.3%10/10

Earnings expanding 55.3% YoY

Price/BookValuation
3.0x8/10

Reasonable price relative to book value

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Areas to Watch

EGP2 concerns · Avg: 3.0/10
P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

PEG RatioValuation
8.422/10

Expensive relative to growth rate

LINE4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-1.2%2/10

ROE of -1.2% — below average capital efficiency

Revenue GrowthGrowth
-0.2%2/10

Revenue declined 0.2%

Altman Z-ScoreHealth
0.812/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : EGP

The strongest argument for EGP centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 39.8% and operating margin at 40.2%.

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bear Case : EGP

The primary concerns for EGP are P/E Ratio, PEG Ratio.

Bear Case : LINE

The primary concerns for LINE are EPS Growth, Return on Equity, Revenue Growth.

Key Dynamics to Monitor

EGP profiles as a mature stock while LINE is a turnaround play — different risk/reward profiles.

EGP is growing revenue faster at 9.1% — sustainability is the question.

EGP generates stronger free cash flow (127M), providing more financial flexibility.

Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

EGP scores higher overall (61/100 vs 34/100), backed by strong 39.8% margins. LINE offers better value entry with a 75.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

EastGroup Properties Inc

REAL ESTATE · REIT - INDUSTRIAL · USA

EastGroup Properties, Inc. (NYSE: EGP), an S&P MidCap 400 company, is a self-managed capital real estate investment trust focused on the development, acquisition and operation of industrial properties in Sunbelt's major markets in the United States. with an emphasis on the states of Florida, Texas, Arizona, California and North Carolina.

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm focused on regenerative medicine, specifically developing cutting-edge cell therapy solutions for treating debilitating conditions, including ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust network of strategic collaborations, Lineage is poised to transform patient care through innovative therapeutic interventions. The company's commitment to advancing its diverse product pipeline and expediting clinical research positions it as an attractive investment opportunity for institutional investors seeking to engage in the forefront of healthcare advancements.

Visit Website →

Want to dig deeper into these stocks?